ClinicalTrials.gg

Program

Deuruxolitinib

Also written as “CTP-543”, “[14C]-CTP-543” and “CTP-543, 16 mg (2 x 8 mg tablet)”.

Its studies are mostly in Alopecia Areata · Renal Insufficiency, led by Sun Pharmaceutical Industries.

Furthest: phase 3, since Mar 29, 201923 company-led studies, 3 open or runningNext primary completion: May 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sun Pharmaceutical Industries233 open or runningphase 3since Mar 29, 2019May 16, 2016May 2027phase 3 · NCT03898479

Also a collaborator on its studies: Celerion.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since May 16, 2016.

  1. May 6, 2019Phase 2 study in Alopecia AreataNCT03941548 · 66 enrolled · United States, Canada
  2. Sep 5, 2019Phase 1 study in Healthy VolunteersNCT04092712 · 6 enrolled · United States
  3. Mar 11, 2020Phase 1 study in Healthy VolunteersNCT04309643 · 21 enrolled · United States
  4. Aug 16, 2020Phase 3 study in Alopecia AreataNCT04518995 · 706 enrolled · United States, Canada, France and more
  5. Feb 4, 2021Phase 1 study in Healthy VolunteersNCT04743414 · 22 enrolled · United States
  6. Mar 3, 2021Phase 2 study in Alopecia AreataNCT04784533 · 317 enrolled · United States
  7. Mar 10, 2021Phase 3 study in Alopecia AreataNCT04797650 · 517 enrolled · United States, Canada, France and more
  8. Apr 9, 2021Phase 1 study in Healthy VolunteersNCT04843540 · 22 enrolled · United States
  9. Sep 3, 2021Phase 3 study in Alopecia AreataNCT05041803 · 407 enrolled · France, Germany, Hungary and more
  10. Jan 5, 2022Phase 1 study in Healthy VolunteersNCT05192369 · 48 enrolled · United States
  11. Jun 30, 20224 phase 1 studiesNCT05468749, NCT05467722, NCT05467709 and 1 more
  12. Jul 26, 2022Phase 1 study in Health VolunteersNCT05478772 · 18 enrolled · United States
  13. Jul 29, 2025Phase 3 study in Alopecia AreataNCT07133308 · 355 planned · United States, Canada
  14. May 22, 2026Phase 3 study in Alopecia AreataNCT07617597 · 78 planned · Japan

Ahead

  1. May 2027Primary completion: phase 3 study in Alopecia AreataNCT03898479
  2. Feb 2028Primary completion: phase 3 study in Alopecia AreataNCT07617597
  3. May 2028Primary completion: phase 3 study in Alopecia AreataNCT07133308

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07617597Alopecia Areata · Japan3RecruitingFeb 202878
NCT07133308Alopecia Areata · United States, Canada3RecruitingMay 2028355
NCT05478772Health Volunteers · United States1CompletedAug 6, 202218
NCT05468749Renal Insufficiency · United States1CompletedOct 20, 202216
NCT05467722Hepatic Impairment · United States1CompletedSep 15, 202221
NCT05467709Health Volunteers · United States1CompletedJun 30, 202220
NCT05467696Health Volunteers · United States1CompletedJun 26, 202216
NCT05192369Healthy Volunteers · United States1CompletedJan 28, 202248
NCT05041803Alopecia Areata · France, Germany, Hungary and more3CompletedJul 18, 2024407
NCT04843540Healthy Volunteers · United States1CompletedJun 24, 202122
NCT04797650Alopecia Areata · United States, Canada, France and more3CompletedJun 8, 2022517
NCT04784533Alopecia Areata · United States2CompletedMay 16, 2023317
NCT04743414Healthy Volunteers · United States1CompletedMar 27, 202122
NCT04518995Alopecia Areata · United States, Canada, France and more3CompletedApr 19, 2022706
NCT04309643Healthy Volunteers · United States1CompletedJun 25, 202021
NCT04092712Healthy Volunteers · United States1CompletedSep 11, 20196
NCT03941548Alopecia Areata · United States, Canada2CompletedApr 10, 202066
NCT03898479Alopecia Areata · United States, Canada3Active, not recruitingMay 20271,000
NCT03880136Healthy · United States1CompletedApr 5, 201914
NCT03811912Alopecia Areata · United States2CompletedNov 21, 201957
NCT03137381Alopecia Areata · United States2CompletedJul 8, 2019149
NCT02960945Healthy · United States1CompletedJan 201712
NCT02777008Healthy · Australia1CompletedDec 201677

How it is read

Names in the registry

  • “CTP-543”, 21 entries
  • “Deuruxolitinib”, 2 entries
  • “[14C]-CTP-543”, 1 entry
  • “CTP-543, 16 mg (2 x 8 mg tablet)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.